Merck Sharp & Dohme LLC has disclosed compounds acting as GTPase KRAS inhibitors reported to be useful for the treatment of cancer.

University of California Oakland has divulged GTPase KRAS (G12R mutant) inhibitors reported to be useful for the treatment of cancer.

Jacobio Pharmaceuticals Co. Ltd. has described GTPase KRAS (mutant) inhibitors reported to be useful for the treatment of cancer.

Hangzhou Zhongmei Huadong Pharmaceutical Co. Ltd. has described GTPase KRAS (G12D mutant) inhibitors reported to be useful for the treatment of cancer.

Shanghai Apeiron Biotechnology Co. Ltd. has described GTPase KRAS (G12D mutant) inhibitors reported to be useful for the treatment of cancer.

Ensem Therapeutics Inc. has disclosed quinazoline derivatives acting as GTPase KRAS (G12D mutant) inhibitors reported to be useful for the treatment of cancer.

Mirati Therapeutics Inc. has synthesized GTPase KRAS and its mutant inhibitors reported to be useful for the treatment of cancer.

Mirati Therapeutics Inc. has identified compounds acting as GTPase KRAS and/or GTPase KRAS (mutant) inhibitors reported to be useful for the treatment of cancer.

Kumquat Biosciences Inc. has identified GTPase KRAS and KRAS (G12D mutant) inhibitors reported to be useful for the treatment of cancer, particularly solid tumors and hematological cancer.

Eli Lilly & Co. has identified GTPase KRAS and its mutant inhibitors reported to be useful for the treatment of cancer.